Murine Anti-Factor VIII

Clone GMA-8041

Factor VIII (FVIII) is a heterodimer consisting of a heavy chain (ranging in mass from 90 to 200 kDa) bound via metal ions to a light chain (80 kDa). In plasma, FVIII circulates in an inactive form bound to von Willebrand factor. Following activation by factor Xa or thrombin, factor VIIIa can function as cofactor for the enzyme factor IXa in the activation of factor X in the presence of phospholipid and Ca^{2+}. Absent or defective FVIII is the cause of the X-linked recessive bleeding disorder hemophilia A. GMA-8041 is suitable for ELISA and Western blot applications.

Description

Antibody Source:	mouse monoclonal, IgG_1
Antigen Species Bound:	human
Specificity:	FVIII light chain
Immunogen:	recombinant human FVIII light chain (residue numbers1689-2332)

Formulation and Storage

Purity:	Purified by protein G affinity chromatography from serum-free cell culture supernatant.
Product Formulation:	Lyophilized from a ≥1 mg/ml solution in 20 mM NaH_2PO_4 0.15 M NaCl, 1.0% (w/v) mannitol, pH 7.4. Concentration determined by absorbance measurement at 280 nm and using an extinction coefficient of 1.4 ($\varepsilon_{0.1\%}$).
Reconstitution:	Reconstitute with deionized water.
Storage:	Store lyophilized or reconstituted and aliquoted material at -20°C for prolonged periods. Avoid freeze-thaw cycles. Alternatively, add 0.02% (w/v) sodium azide to reconstituted solution and store at 4°C.
Country of Origin:	USA
Size Options:	0.1 mg or 0.5 mg

Applications

Working Concentration:	Approximately 1-5 µg/ml. Researcher should titer antibody in specific assay.
ELISA:	Binds immobilized human FVIII.
Immunoblotting:	Western blot detects light chain of human FVIII.





References

[1] M. Elnaggar, A. Al-Mohannadi, D. Kizhakayil, C. M. Raynaud, S. Al-Mannai, G. Gentilcore, I. Pavlovski, A. Sathappan, N. Van Panhuys, C. Borsotti, A. Follenzi, J-C. Grivel, S. Deola. Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A. (2020). *Molecular Therapy: Methods & Clinical Development.* 17:1-12.

For in vitro research only. Not for use as a diagnostic or therapeutic. All sales governed by Warranty Policy located at: https://greenmoab.com/about-gma/warranty-policy/

PO Box 1283 www.greenmoab.com Burlington, VT T 802.865.6230 F 802.865.0115